Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine

Journal of Gastroenterology

Volumn 47, Issue 3, 2012, Pages 321-333

  Shimasaki, Takeo ^a,b   Ishigaki, Yasuhito ^a   Nakamura, Yuka ^a   Takata, Takanobu ^a   Nakaya, Naoki ^a   Nakajima, Hideo ^a   Sato, Itaru ^a   Zhao, Xia ^c   Kitano, Ayako ^b   Kawakami, Kazuyuki ^b   Tanaka, Takuji ^a   Takegami, Tsutomu ^a   Tomosugi, Naohisa ^a   Minamoto, Toshinari ^b   Motoo, Yoshiharu ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Gemcitabine; Glycogen synthase kinase 3 TP53INP1; Pancreatic cancer

Indexed keywords

1 (4 METHOXYBENZYL) 3 (5 NITRO 2 THIAZOLYL)UREA; GEMCITABINE; GLYCOGEN SYNTHASE KINASE 3BETA; NUCLEAR PROTEIN; TUMOR PROTEIN 53 INDUCED NUCLEAR PROTEIN 1; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SENSITIZATION; EMBRYO; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLES; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863109797     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0484-9     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66. (Pubitemid 46148091)
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
3. Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer. 2004;91:673-7. (Pubitemid 39141622)
4. Okusaka T, Kosuge T. Systemic chemotherapy for pancreatic cancer. Pancreas. 2004;28:301-4. (Pubitemid 38437328)
5. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049-57. (Pubitemid 38410779)
6. Schneider G, Siveke JT, Eckel F, Schmid RM. Pancreatic cancer: basic and clinical aspects. Gastroenterology. 2005;128:1606-25. (Pubitemid 40692555)
7. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13. (Pubitemid 27251144)
8. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969-72. (Pubitemid 30637716)
9. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897-909. (Pubitemid 37328891)
10. Giroux V, Dagorn JC, Iovanna JL. A review of kinases implicated in pancreatic cancer. Pancreatology. 2009;9:738-54.
11. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6. (Pubitemid 46972777)
12. Furukawa T. Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside. J Gastroenterol. 2008;43:905-11.
13. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 2007;32:577-95. (Pubitemid 46481289)
14. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci. 2004;29:95-102. (Pubitemid 38186580)
15. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multitasking kinase. J Cell Sci. 2003;116:1175-86. (Pubitemid 36410657)
16. Harwood AJ. Regulation of GSK-3: a cellular multiprocessor. Cell. 2001;105:821-4. (Pubitemid 32635083)
17. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov. 2004;3:479-87. (Pubitemid 38807530)
18. Meijer L, Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci. 2004;25: 471-80. (Pubitemid 39149703)
19. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, et al. Deregulated GSK3β activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun. 2005;334:1365-73. (Pubitemid 41074725)
20. Shakoori A, Mai W, Miyashita K, Yasumoto K, Takahashi Y, Ooi A, et al. Inhibition of GSK-3β activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci. 2007;98: 1388-93. (Pubitemid 47241761)
21. Miyashita K, Kawakami K, Nakada M, Mai W, Shakoori A, Fujisawa H, et al. Potential therapeutic effect of glycogen synthase kinase 3β inhibition against human glioblastoma. Clin Cancer Res. 2009;15:887-97.
22. Mai W, Kawakami K, Shakoori A, Kyo S, Miyashita K, Yokoi K, et al. Deregulated GSK3β sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase. Clin Cancer Res. 2009;15:6810-9.
23. Miyashita K, Nakada M, Shakoori A, Ishigaki Y, Shimasaki T, Motoo Y, et al. An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3β. Anticancer Agents Med Chem. 2009;9:1114-22.
24. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature. 2000;406:86-90. (Pubitemid 30460216)
25. Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3 in TNF-α-induced NF-κB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol. 2002;283:G204-11. (Pubitemid 34666179)
26. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005;65:2076-81. (Pubitemid 40490111)
27. Wilson W III, Baldwin AS. Maintenance of constitutive IκB kinase activity by glycogen synthase kinase-3α/β in pancreatic cancer. Cancer Res. 2008;68:8156-63.
28. Mamaghani S, Patel S, Hedley DW. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-κB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy. BMC Cancer. 2009;9:132.
29. Ougolkov A, Zhang B, Yamashita K, Bilim V, Mai M, Fuchs SY, et al. Associations among β-TrCP, an E3 ubiquitin ligase receptor, β-catenin, and NF-κB in colorectal cancer. J Natl Cancer Inst. 2004;96:1161-70. (Pubitemid 39207052)
30. Mai W, Miyashita K, Shakoori A, Zhang B, Yu ZW, Takahashi Y, et al. Detection of active fraction of glycogen synthase kinase 3β in cancer cells by nonradioisotopic in vitro kinase assay. Oncology. 2006;71:297-305.
31. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem. 2003;278:45937-45. (Pubitemid 37432740)
32. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys. 1979;5:85-91. (Pubitemid 9120186)
33. Jiang PH, Motoo Y, Sawabu N, Minamoto T. Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells. World J Gastroenterol. 2006;12: 1597-602.
34. Holcomb B, Yip-Schneider M, Schmidt CM. The role of nuclear factor κB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas. 2008;36:225-35. (Pubitemid 351440925)
35. Diamantidis M, Tsapournas G, Kountouras J, Zavos C. New aspects of regulatory signaling pathways and novel therapies in pancreatic cancer. Curr Mol Med. 2008;8:12-37. (Pubitemid 351516822)
36. Hamacher R, Schmid RM, Saur D, Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer. 2008;7:64.
37. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009;69: 2400-7.
38. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69:5820-8.
39. Cano CE, Gommeaux J, Pietri S, Culcasi M, Garcia S, Seux M, et al. Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function. Cancer Res. 2009;69: 219-26.
40. Tomasini R, Samir AA, Vaccaro MI, Pebusque MJ, Dagorn JC, Iovanna JL, et al. Molecular and functional characterization of the stress-induced protein (SIP) gene and its two transcripts generated by alternative splicing. SIP induced by stress and promotes cell death. J Biol Chem. 2001;276:44185-92.
41. Okamura S, Arakawa H, Tanaka T, Nakanishi H, Ng CC, Taya Y, et al. p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Mol Cell. 2001;8:85-94. (Pubitemid 32772907)
42. Gironella M, Seux M, Xie MJ, Cano C, Tomasini R, Gommeaux J, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A. 2007;104: 16170-5. (Pubitemid 350099380)
43. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002;2:910-7. (Pubitemid 37328892)
44. Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M, et al. Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol. 2001;21:4684-99. (Pubitemid 32588250)
45. Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer. 2007;120:1355-63.
46. Nakahara O, Takamori H, Tanaka H, Sakamoto Y, Ikuta Y, Furuhashi S, et al. Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer. Int J Clin Oncol. 2010;15:39-45.